Amlexanox for Mast Cell Activation Syndrome, Opportunistic Salpingectomy for Ovarian Cancer Prevention, Adaptive Deep Brain Stimulation for Parkinson's, and Chinese Brain-Computer Interface Development

Broadcast from KSQD, Santa Cruz on 8-20-2026:

An emailer asks about amlexanox for mast cell activation syndrome (MCAS). Dr. Dawn first walks through MCAS diagnostic criteria—requiring symptoms across at least two of four categories (skin, low blood pressure, abdominal, respiratory), with serum tryptase testing performed both during and after a flare. She grades amlexanox as a C: originally FDA-approved only as a topical paste for canker sores, later approved in Japan as an asthma treatment, but never validated for MCAS and pushed largely by a single compounding pharmacy and its influencer clones. She recommends conventional agents first—antihistamines, montelukast, cromolyn, quercetin, aspirin for flushing, and Xolair anti-IgE antibodies for severe cases—plus microcrystalline cellulose as the safest capsule filler if compounding of amellanox is pursued.

Most ovarian cancers—including nearly all fatal cases—actually originate in the fimbriae of the fallopian tubes rather than the ovaries themselves. Opportunistic salpingectomy tacks a five-minute fallopian tube removal onto any abdominal surgery (tubal ligation, hernia repair, gallbladder, appendectomy), potentially reducing lifetime ovarian cancer risk by 65% -80% based on epidemiological data from Swedish, Canadian, and Danish registry studies. Dr. Dawn recommends particular consideration for non-childbearing women with BRCA1/2 or family history of breast or ovarian cancer.

Deep brain stimulator devices manufactured after 2020 (about 40,000 U.S. patients) contain adaptive-DBS capability that can be activated via firmware upgrade without additional surgery. Rather than delivering constant stimulation like older devices, adaptive DBS reads beta oscillations (13-30 Hz motor-control brainwaves) in the basal ganglia and modulates output in real time—reducing stimulation as L-DOPA peaks from drugs and increasing it as medication wears off, smoothing the swings between agitation and freezing. Sleep improvement has emerged as a notable secondary benefit, potentially slowing disease progression. The technology is also being investigated for dystonia, essential tremor, OCD, and Tourette's syndrome.

Chinese company StarMed is developing brain-computer interfaces closely resembling Neuralink designs, benefiting from aggressive government funding, large patient populations, and reduced tort liability. One trial uses an eight-probe device placed atop the dura mater (avoiding brain penetration) connected to a pneuma